rs1085307426
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000020.3(ACVRL1):c.1436G>A(p.Arg479Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,568 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R479P) has been classified as Pathogenic.
Frequency
Consequence
NM_000020.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ACVRL1 | NM_000020.3 | c.1436G>A | p.Arg479Gln | missense_variant | 10/10 | ENST00000388922.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ACVRL1 | ENST00000388922.9 | c.1436G>A | p.Arg479Gln | missense_variant | 10/10 | 1 | NM_000020.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151854Hom.: 0 Cov.: 31
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461714Hom.: 0 Cov.: 35 AF XY: 0.00 AC XY: 0AN XY: 727154
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151854Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74132
ClinVar
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 2 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Dec 17, 2018 | The ACVRL1 c.1436G>A;p.Arg479Gln variant has been described in families and individuals with hereditary hemorrhagic telangiectasia (HHT) or pulmonary arterial hypertension (PAH) and has been described as segregating with disease (Bayrak-Toydemir 2006, Bayrak-Toydemir 2008, Fujiwara 2008, Gedge 2007, Lesca 2006, McDonald 2011). It is reported as pathogenic in ClinVar (Variation ID: 426035) and is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. The arginine at codon 479 is highly conserved and computational algorithms (SIFT, PolyPhen2) predict this variant is deleterious. Additionally, this variant has been shown to have reduced function (Ricard 2010). Based on available information, this variant is considered pathogenic. REFERENCES Bayrak-Toydemir P et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A. 2006 Mar 1;140(5):463-70. Bayrak-Toydemir P et al. Likelihood ratios to assess genetic evidence for clinical significance of uncertain variants: hereditary hemorrhagic telangiectasia as a model. Exp Mol Pathol. 2008 Aug;85(1):45-9.. Fujiwara M et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J. 2008 Jan;72(1):127-33. Gedge F et al. Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations. J Mol Diagn. 2007 Apr;9(2):258-65. Lesca G et al. Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat. 2006 Jun;27(6):598. McDonald J et al. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet. 2011 Apr;79(4):335-44. Ricard N et al. Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood. 2010 Sep 2;116(9):1604-12. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Jan 09, 2023 | The ACVRL1 c.1436G>A variant is classified as Likely Pathogenic (PS4_Moderate, PM2_supporting, PS3_supporting, PM1_supporting, PP3). The ACVRL1 c.1436G>A variant is a single nucleotide change in exon 10/10 of the ACVRL1 gene, which is predicted to change the amino acid arginine at position 479 in the protein to glutamine. The variant has been reported in multiple individuals with a clinical presentation of HHT (PMID:34872578, PMID:32300199, PMID:16705692) (PS4_Moderate). The variant is rare in population databases (gnomAD allele frequency = 0.0013%; 2 het and 0 hom in 151854 sequenced alleles; highest frequency = 0.0029%, Non-Finnish European population) (PM2_supporting). Functional studies show a deleterious effect of this variant (PMID:20501893) (PS3_supporting). This variant is located in the conserved serine/threonine kinase domain (PMID:34872578) (PM1_supporting). Computational predictions support a deleterious effect on the gene or gene product (PP3). The variant has been reported in dbSNP (rs1085307426) and has been reported as Pathogenic by other diagnostic laboratories (ClinVar Variation ID: 426035). It has not been reported in HGMD. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 27, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 479 of the ACVRL1 protein (p.Arg479Gln). This variant is present in population databases (no rsID available, gnomAD 0.007%). This missense change has been observed in individuals with hemorrhagic telangiectasia (PMID: 16470787, 16705692, 21158752; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 426035). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACVRL1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ACVRL1 function (PMID: 20501893). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 21, 2022 | PP1_strong, PP3, PP4, PM2_supporting, PS3_supporting, PS4_moderate - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 18, 2021 | The p.R479Q pathogenic mutation (also known as c.1436G>A), located in coding exon 9 of the ACVRL1 gene, results from a G to A substitution at nucleotide position 1436. The arginine at codon 479 is replaced by glutamine, an amino acid with highly similar properties. This mutation has been reported in multiple individuals meeting clinical diagnostic criteria for hereditary hemorrhagic telangiectasia (Bayrak-Toydemir P et al. Am. J. Med. Genet. A, 2006 Mar;140:463-70; Lesca G et al. Hum. Mutat., 2006 Jun;27:598; Giordano P et al. J. Pediatr., 2013 Jul;163:179-86.e1-3) and it has been shown to co-segregate with disease (Bayrak-Toydemir P et al. Exp. Mol. Pathol., 2008 Aug;85:45-9). In addition, an in vitro functional study demonstrated that although this mutation does not disrupt ligand binding, it does interfere with ligand signaling (Ricard N et al. Blood, 2010 Sep;116:1604-12). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pulmonary hypertension, primary, 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | Rare Disease Genomics Group, St George's University of London | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at